The US market for dietary supplements containing hemp ingredients may be approaching a point of either collapsing or rebounding toward the potential expected when the botanical was de-scheduled as a controlled substance.
The direction the market goes depends on different influences, according to witnesses testifying at a recent House hearing looking at the Food and Drug Administration’s position